GlassScriptPhysician profile
Marjorie S Bisenius
NPI 1992731574
$4,718.49
in general payments reported to CMS, 2019-2025
47 companies · $801 in 2025
The $801 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $282 · 2021: $853 · 2022: $735 · 2023: $910 · 2024: $605 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,098.91 | 2019-2025 | Qulipta, Ubrelvy, Viberzi |
| Novo Nordisk INC | $653.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $429.53 | 2019-2025 | Farxiga |
| Amgen INC. | $302.59 | 2019-2025 | Evenity, Prolia |
| Lilly USA, LLC | $263.20 | 2019-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $184.72 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $155.69 | 2020-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $149.24 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $127.44 | 2021-2025 | Qelbree, Qelbree |
| Pfizer INC. | $118.34 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $100.92 | 2019-2024 | Invega Sustenna, Spravato |
| Medtronic, INC. | $98.23 | 2022-2025 | Symplicity G3, Venaseal |
| Takeda Pharmaceuticals U.S.A., INC. | $82.47 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.01 | 2021-2024 | Xifaxan, Trulance |
| Neos Therapeutics, LP | $61.58 | 2022-2024 | Adzenys Xr-Odt |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjorie Bisenius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.